COMMUNIQUÉS West-GlobeNewswire

Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting
03/12/2018
HOUSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of [...]
OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
03/12/2018
CG-806 Pan-FLT3/Pan-BTK Inhibitor Exhibits Favorable Safety Profile and Unexpected Potency on Primary Cells from B-cell Cancer Patients and AML Patients PORTLAND, Ore. and SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- [...]
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
03/12/2018
Data elucidate unique ability of CG-806 to overcome resistance to other FLT3 inhibitors in AML cells SAN DIEGO and TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today [...]
Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications
03/12/2018
Novel small molecule FF-10158 targets integrin alphavbeta3 ( a v β3 ) and alphavbeta5 ( a v β5 ) receptors Expands theragnostic pipeline Potential broad application in the detection and treatment of highly vascularized [...]
Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
03/12/2018
Media Release Event to be held today in San Diego, California Independent experts to discuss data presented at the 2018 ASH Annual Meeting Meeting to be webcast live and archived on www.genmab.com Copenhagen, Denmark; [...]
GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis
03/12/2018
GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis Phase 2 study targeting a patient population with NASH-induced Stage 2 or 3 fibrosis Anti-fibrotic [...]
GENFIT : Lancement aux États-Unis d'une étude de Phase 2 initiée par un investigateur, évaluant nitazoxanide chez des patients avec fibrose NASH
03/12/2018
GENFIT : Lancement aux États-Unis d'une étude de Phase 2 initiée par un investigateur, évaluant nitazoxanide chez des patients avec fibrose NASH Étude de phase 2 ciblant une population de patients atteints de NASH avec [...]
Press release: Terveystalo to become a shareholder in startup company Etsimo Healthcare - harnessing AI to assist the customer and the healthcare professional
03/12/2018
Terveystalo has signed a contract on 27 November to acquire a share of about 20% in Etsimo Healthcare Oy. Etsimo Healthcare was established in 2016 and develops a platform built specifically for healthcare, combining [...]
Rule 2.9 Announcement
03/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 December 2018 [...]
Total voting rights
03/12/2018
Total Voting Rights December 3, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of the Financial Conduct Authority's (the “FCA”) Disclosure Guidance and Transparency Rules, notifies [...]
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
03/12/2018
The AVXS-101, now known as ZOLGENSMA ® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative improvement in [...]
Helsinn and Mundipharma China Pharmaceutical Announce Approval of ALOXI® IV by the National Medical Products Administration (NMPA)
03/12/2018
Helsinn and Mundipharma China Pharmaceutical Announce Approval of ALOXI ® IV by the National Medical Products Administration (NMPA) Approval by the National Medical Products Administration (NMPA) brings ALOXI ® to a [...]
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
03/12/2018
Detailed Phase 2 ITP data show clear correlation between IgG reduction, platelet count increase and reduction of bleeding events ITP program expected to advance to Phase 3 with IV efgartigimod and Phase 2 with [...]
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
03/12/2018
Regulated information – Inside information Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up to $1.6 billion potentially Janssen to pay argenx $300 million in [...]
Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy
03/12/2018
Prospective Study Successfully Identified Mechanisms for AML & MDS Patients’ Nonresponse to Standard Care Treatments and Predicts Best Therapy Options for Evolved Disease SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE [...]
Cellworks Study Predicted Non-Response to Azacitidine in MDS Patients with 100% Accuracy using AI-Driven Biosimulation
03/12/2018
Analysis Uncovered Possible Mechanisms for AZA Resistance that could be Targeted to Induce Response SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a leader in Precision Medicine and a global pioneer [...]
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting
03/12/2018
- Complete Responses Observed in Three of Six Patients at Dose Level 1 and One of Three Patients at Dose Level 2 - - No SAEs of Cytokine Release Syndrome or Neurological Events Observed in Dose Levels 1 or 2 - - [...]
Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
03/12/2018
Data support opportunities to develop best-in-class, durable medicines for hemoglobinopathies CAMBRIDGE, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, [...]
Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition
03/12/2018
Preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show dramatic reductions in bleeds and infusions for first 12 participants with an encouraging safety profile, as of Nov. 2, 2018, data cutoff All [...]

Pages